PHA 543613 hydrochloride
Chemical Name: N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-c]pyridine-5-carboxamide hydrochloride
Purity: ≥98%
Biological Activity
Potent α7 nAChR agonist that displays selectivity over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors. Positively influences sensory gating and memory in in vivo models of schizophrenia. Orally active and brain penetrant.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Background References
-
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia; synthesis and st
Wishka et al.
J.Med.Chem., 2006;49:4425 -
Allosteric modulators of the α7 nicotinic acetylcholine receptor.
Faghih et al.
J.Med.Chem., 2008;51:701 -
Discovery of N-[3R,5R)-1-azabicyclo[3.2.1]ocy-3-yl]furo-[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: in vitro and in vivo activity.
Acker et al.
Bioorg.Med.Chem.Letts., 2008;18:3611
Product Datasheets
Reconstitution Calculator
Molarity Calculator
Citations for PHA 543613 hydrochloride
The citations listed below are publications that use Tocris products. Selected citations for PHA 543613 hydrochloride include:
7 Citations: Showing 1 - 7
-
Facilitation and inhibition of firing activity and N-methyl-D-aspartate-evoked responses of CA1 hippocampal pyramidal cells by alpha7 nicotinic acetylcholine receptor selective compounds in vivo.
Authors: Bali Et al.
Sci Rep 2019;9:9324
-
Cognitive enhancer effects of low Mem. doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats.
Authors: Bali Et al.
Front Pharmacol 2019;10:73
-
Neuroprotective effect of the alpha 7 nicotinic receptor agonist PHA 543613 in an in vivo excitotoxic adult rat model.
Authors: Foucault-Fruchard
Neuroscience 2017;356:52
-
Assessment of the Protection of DArgic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model.
Authors: Sérriàre Et al.
Cell Death Differ 2015;2:61
-
Differential effects of α7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models.
Authors: Bali Et al.
Behav Brain Res 2015;278:404
-
The α7 nicotinic receptor agonist PHA-543613 hydrochloride inhibits Porphyromonas gingivalis-induced expression of interleukin-8 by oral keratinocytes.
Authors: Macpherson Et al.
Front Med (Lausanne) 2014;63:557
-
Electroacupuncture pretreatment attenuates cerebral ischemic injury through α7 nicotinic acetylcholine receptor-mediated inhibition of high-mobility group box 1 release in rats.
Authors: Wang Et al.
J Neuroinflammation 2012;9:24
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsVersaClone cDNA Plasmids
Reviews for PHA 543613 hydrochloride
Average Rating: 5 (Based on 1 Review)
Have you used PHA 543613 hydrochloride?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
We used PHA 543613 in behavioral pharmacology experiments and tested its cognitive enhancer effect. PHA 543613 was found effective in different behavioral paradigms, and in different models of cognitive impairment. For instance, PHA 543613 dose-dependently reversed scopolamine induced transient amnesia in the spontaneous alternation (t-maze) task of rats.
